Genomic Testing in Cancer Market Size, Share, Competitive Landscape and Trend Analysis Report by Technology, by Indication and by Test Type : Opportunity Analysis and Industry Forecast, 2023-2032

Scope of the Study

The Genomic testing in cancer market study provides a detailed analysis pertaining to the global market size & forecast, segmental splits, regional & country-level outlook, market dynamics & trends, Porters’ five force analysis, value chain analysis, competitive landscape, market share analysis, and patent analysis.

Segmental Outlook

The global Genomic testing in cancer market is segmented depending on by technology, by indication, by test type.

Segmental analysis is offered (real time and forecast) in both quantitative and qualitative terms. This helps the clients to identify the most lucrative segment to consider for their further investments, based on the comprehensive backend analysis about the segmental performance, in addition to brief understanding of the operating companies and their development activities with respect to the market.

Market Opportunities

Genomic testing in cancer market is witnessing remunerative opportunities for expansion in the near future.

Graph for representation purpose only

Regional Outlook

The Genomic testing in cancer market is analyzed across four key regions, which include North America, Europe, Asia-Pacific, and LAMEA. The key countries contributing toward the growth of the market include:

• North America: U.S., Canada, and Mexico

• Europe: Germany, UK, Italy, Spain, France, and rest of Europe

• Asia-Pacific: India, China, South Korea, Japan, Australia, and rest of Asia-Pacific

• LAMEA: Brazil, Saudi Arabia, South Africa, and rest of LAMEA

Key companies profiled in the report are Illumina, Inc., QIAGEN N.V., Thermo Fisher Scientific, Inc., BGI Genomics Co., Ltd., Roche Holding AG, Pacific Biosciences of California, Inc., Agilent Technologies, Inc., Danaher Corporation, Bio-Rad Laboratories, Inc., IntegraGen SA

Genomic testing in cancer market Attractiveness Index, By Region, 2024

Graph for representation purpose only

Competitive Scenario

The report profiles the top players operating across the globe along with market share analysis, and an outlook of top player positioning. In addition, the study focuses on the developmental strategies such as product launch, mergers & acquisitions, and collaborations adopted by the key players to maintain a competitive edge in the marketspace.

Report Coverage

• Growth projections: 2024 to 2032

• Major segments covering by technology, by indication, by test type

• Market dynamics and trends

• Competitive landscape reporting

Research Methodology

AMR offers its clients with comprehensive research and analysis based on a wide variety of factual inputs that majorly include interviews with professionals in the industry, regional intelligence, and reliable statistics obtained from multiple resources. The in-house industry experts play an important role in designing analytic tools and models, tailored to the requirements of the client for a particular industry segment. These analytical tools and models refine the statistics & data and enhance the accuracy of our recommendations and advice.

  Genomic Testing in Cancer Market Report Highlights

Aspects	Details
By Technology	PCR Next Generation Sequencing Microarrays Other Technologies
By Indication	Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Other Cancers
By Test Type	Gene Expression Testing Genomic Risk Assessment Whole Genome Sequencing Other Test Types
By Region	North America  (U.S., Canada, Mexico) Europe  (France, Germany, Italy, Spain, UK, Russia, Rest of Europe) Asia-Pacific  (China, Japan, India, South Korea, Australia, Thailand, Malaysia, Indonesia, Rest of Asia-Pacific) LAMEA  (Brazil, South Africa, Saudi Arabia, UAE, Argentina, Rest of LAMEA)
Key Market Players	Danaher Corporation, Pacific Biosciences of California, Roche Holding AG, BGI Genomics Co., Illumina, Bio-Rad Laboratories, Thermo Fisher Scientific, Agilent Technologies, QIAGEN N.V., IntegraGen SA